Interestingly, psoriasis is recognized as an autoimmune skin disease, and the IL-17 signaling pathway, a major regulator of autoimmune diseases, has been found to be closely linked to the therapeutic mechanism of SHTLS (Figure 3D). This evidence concerns the gene IL17A and psoriasis.